Science at Sanofi
Events
Stay up to date and register for the latest events and view webinar recordings
Expanding the landscape of Type 2 inflammation
From shared pathways toward therapeutic innovation
Understanding the Burden of RSV: Impact of Infants and Healthcare Providers
Join Professor Yeo Kee Thai for an in-depth exploration of Respiratory Syncytial Virus (RSV) burden in Singapore and its significant impact on our healthcare system. Through evidence-based insights, he demonstrates how RSV affects not only premature infants but also healthy full-term babies, with 53% of PICU admissions being previously healthy term infants. His presentation addresses Singapore's unique year-round RSV activity pattern and its implications for infant protection strategies.
Uncovering the Impact of RSV: A Case Study
Join Professor Lee Bee Wah as she presents a compelling case study of Baby E, demonstrating the real-world impact of RSV infection in infants. Through this clinical narrative, Prof. Lee walks us through the journey of a 7-month-old infant from initial RSV diagnosis to hospitalization, highlighting the challenges of managing bronchiolitis and its potential long-term respiratory consequences. This insightful presentation illustrates why RSV prevention is crucial in protecting our youngest patients, making it essential viewing for healthcare professionals managing infant and pediatric care.
Beyond the Trials: Nirsevimab's Real-World Evidence in Action
Join Dr. Juan Pablo Torres Torretti for an instructive presentation on the real-world implementation and impact of nirsevimab for RSV prevention. Drawing from groundbreaking data from Chile—the first Southern Hemisphere country to implement a nationwide nirsevimab immunization program—Dr. Torres reveals remarkable outcomes including 80-95% reduction in RSV hospitalizations and 85% reduction in PICU admissions. The presentation highlights Chile's successful strategy of protecting both newborns and infants under six months, achieving over 90% coverage rates with an excellent safety profile. Dr. Torres also shares comparative data from other countries including Spain's NIRSE-GAL study, demonstrating consistent effectiveness across different healthcare systems and providing compelling evidence for nirsevimab's role in transforming RSV prevention globally.
Nirsevimab in Focus: Clinical Insights into RSV Protection
Join Professor Yung Chee Fu as he presents the compelling clinical evidence behind nirsevimab (Beyfortus), a breakthrough single-dose solution for RSV protection in all infants. Through comprehensive trial data, Prof. Yung demonstrates nirsevimab's remarkable 70-86% efficacy in preventing RSV-related hospitalizations across all infant populations. The presentation highlights how Nirsevimab provides extended protection beyond five months, making it particularly valuable for Singapore's year-round RSV season, while maintaining an excellent safety profile across all gestational ages.
Demystifying Pompe Disease: Asia Pompe Expert Forum - Chapter 1: Introduction to Pompe Disease
European Academy of Allergy and Clinical Immunology (EAACI) Congress Highlights
13–16 June 2025, in Glasgow, Scotland.
Cutting-Edge Science
Discover medical insights and trends from trusted sources and key opinion leaders.
Updated Evidence from the EVEREST Phase 4 Trial
First, prospective, head-to-head data comparing Dupilumab and Omalizumab in CRSwNP and asthma patients.
Management of Hypertension in Diabetic Nephropathy Patients - Dr. SP Chan
Join Dr. S. P. Chan, Consultant Endocrinologist, as she discusses key principles in managing hypertension in patients with diabetes, with a special focus on diabetic nephropathy.
In this video, Dr. Chan answers frequently asked questions and shares practical insights to help healthcare professionals optimize care and protect kidney health in diabetic patients.
Beyfortus®: Made with All Infants in Mind to Protect Against RSV
Up to 75% of RSV-associated hospitalisations occur in healthy and full-term children.2 Recent studies have shown that nirsevimab provided up to 90% protection against hospitalisation from severe RSV LRTI in infants during their first RSV season.3
Personalizing Cardiovascular Care in Asian Populations: Insights on Antiplatelet Safety & Lipid Risk
Please log in or register to continue reading.
Request-form
